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1. List of Abbreviations 
 
Abbreviation Full forms 
5-FU 5-Flurouracil 
AP-1            Activator Protein-1 
Apaf-1 Adaptor Protein Apoptotic Protease Activating Factor-1 
Ask-1              Apoptosis Signal Regulating Kinase-1 
Bak Bcl-2 homologous antagonist 
Bax Bcl-2 associated X protein 
Bcl-2               B cell lymphoma-2 
Bcl-xl              B cell lymphoma-extra large 
BH3 Bcl-2 Homology Domain 
BID BH3 interacting domain death agonist 
BIR Baculovirus IAP repeat 
CD95 Cluster of Differentiation 95 
C-IAP             Baculovirus IAP repeat containing protein-2 
DIOC(6)3       3-3ʹ dihexyloxacarbcyanine iodide 
DISC Death Inducing Signalling Complex 
DR5 Death Receptor 5 
ETC Electron transport chain 
FACS    Fluorescence Activated Cell Sorting 
FADD Fas-Associated Death Domain 
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FITC Fluorescein isothiocynate 
IAP Inhibitor of Apoptosis Protein  
JNK   c-Jun N-terminal kinases 
MAPK Mitogen Activated Protein Kinase 
MKK7 Mitogen Activated Protein Kinase Kinase 
NAIP Baculovirus IAP repeat containing protein-1 
NF- kB           Nuclear factor kappa B 
PBS Phosphate Buffer Saline 
RIP-1             Receptor Interacting Protein-1 
Smac Second Mitochondrial Derived Activator of Caspase 
t-BID truncated BID 
TNF Tumour Necrosis Factor  
TRADD TNFR-Associated Death Domain 
TRAIL TNF Related Apoptosis Inducing Complex 
WIP-1            Wild type p53 induced phosphatase-1 
XIAP X-linked Inhibitor of Apoptosis Protein 
Zvad benzyloxycarbonil-Val-Ala-DL-Asp-fluoromethylketone 
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2. Abstract 
 
The induction of programmed cell death (apoptosis) in tumour cells is an essential 
cellular and molecular process in response to cancer treatment and important for its 
success. Classically two forms of apoptosis have been distinguished, the extrinsic 
and the intrinsic apoptosis. Recently novel mechanisms have been proposed that 
blur the lines between the two apoptosis pathways. One of these novel mechanisms 
has been proposed by the Mohr/Zwacka laboratory. It involves a new death 
receptor-independent caspase-8 inducing complex and modulation by the TRAIL-
R2 (DR5). The DR5 modulation appears to be mediated by JNK activation, up 
regulation of a phosphatase and subsequent dephosphorylation of Bid.  
Dephosphorylated Bid can be cleaved by active caspase-8 and can then convey 
the apoptotic signal onto mitochondria, which respond with the release of 
proapoptotic factors such as cytochrome c and Smac/DIABLO into the cytosol. As 
the release of Smac/DIABLO is important in apoptosis and possibly impaired in 
DR5-silenced cells, we developed a FACS based Smac/DIABLO release assay in 
5-Flurouracil (5-FU) stimulated HCT116 cancer cells. Using this assay we found 
that DR5 knock-down cells show a markedly reduced Smac/DIABLO release, which 
corresponds to decreased mitochondrial membrane depolarisation in these cells. 
These mechanistic differences can explain the significantly reduced apoptosis in 5-
FU treated DR5 silenced HCT116 cells. Moreover, this FACS method is a useful 
tool to understand apoptosis signalling in cancer cells. 
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3. Introduction  
 
The ability to modulate the life or death of a cell is called Apoptosis. It helps to 
monitor mitochondrial and cytoplasmic homeostasis, genomic DNA integrity and 
development of cells. It detects potentially dangerous cells such as virally infected 
cells or genetically damaged cells and is associated with typical morphological 
features like cell shrinkage, chromatin condensation, cytoplasmic membrane 
blebbing, DNA fragmentation and externalization of phosphatidylserine on the cell 
membrane (Thornberry and Lezabnik, 1998). 
Apoptosis can also be deregulated in variety of diseases. Uncontrolled apoptosis 
can lead to immune response against body’s own cells and tissues leading to 
autoimmune diseases or it can lead to excessive cell proliferation causing cancer. 
In order to understand how apoptosis regulates the cell function in normal conditions 
and in diseased state, the mechanism of apoptosis in mammalian cells was 
discovered and two apoptotic pathways were elucidated namely the extrinsic 
pathway and the intrinsic pathway. The extrinsic pathway involves death receptor 
mediated interactions, in which the receptors are members of Tumour Necrosis 
Factor (TNF) receptor gene superfamily including TNF receptor (TNFR-1), CD95 
(Fas or APO-1), Death Receptor 3 (DR3), TNF-related apoptosis inducing ligand 
receptor-1 (TRAIL-R1 or DR4) and TRAIL-R2 (DR5) (Falschelehner et al, 2006). 
The death receptors carry a common cysteine rich extracellular domain and a 
conserved stretch of 80 amino acids called death domain in the intracellular region 
which is essential for apoptosis (Ozoren and El-Deiry, 2003). Upon ligand binding, 
recruitment of cytoplasmic adaptor proteins such as Fas associated death domain 
(FADD) or TNFR associated death domain (TRADD) takes place, which in turn bind 
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to pro-caspase 8 thereby forming a death inducing signalling complex (DISC). The 
auto-catalytic activation of caspase 8 triggers the execution phase of apoptosis 
leading to downstream activation of caspase 3, 6 and 7 and programmed cell death 
as shown in figure 1. Caspases are group of endonucleases which are produced as 
inactive pro-caspases called as zymogens. Many models have been proposed for 
initiator caspase activation. Caspases can be activated by ‘induced proximity model’ 
(Salvesen and Dixit, 1999) in which pro-caspases are self-activated when they are 
brought into close proximity of each other at the death receptor. For example, the 
recruitment of caspase 8 molecules to the DISC complex at the death receptor by 
FADD molecule leads to their activation. A model called as ‘proximity induced 
dimerisation’ (Shi et al, 2004) on the other hand states that initiator caspases are 
activated by dimerisation. Chao et al (2005) has also proposed a model to describe 
initiator caspases activation. According to this model, initiator caspase interact with 
adaptor protein such as when caspase 9 interact with apoptosome complex 
consisting of cytochrome c and Apaf-1 which causes conformational changes in the 
active site of the caspase leading to its activation. 
Effector caspases on the other hand are activated by cleavage mediated by initiator 
caspases which leads to conformational changes creating a functionally mature 
protein (Reidl and Shi, 2004). The activated effector caspases lead to DNA damage, 
membrane blebbing and all the characteristic features of apoptosis. Activation of 
effector caspases can also be cell type dependent. In type 1 cells, effector caspases 
are directly activated by caspase 8, whereas in type 2 cells, the intrinsic pathway of 
apoptosis is additionally triggered, which then leads to activation of effector 
caspases and programmed cell death (Mcllwain et al, 2013). The intrinsic pathway 
is normally initiated by non-receptor mediated stimuli that causes cellular stress and 
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Figure 1-Schematic of extrinsic and intrinsic pathways of apoptosis. The 
extrinsic pathway causes programmed cell death by caspase 8 activation whereas 
the intrinsic pathway involves mitochondrial membrane permeabilisation and release 
of mitochondrial proteins from inner membrane and formation of apoptosome complex 
to mediate apoptosis (Li and Sheng, 2012). 
 
directly target the cells leading to mitochondria mediated apoptosis. The stimuli 
include growth factors, cytokines, toxins, viral infection, free radicals and cytotoxic 
drugs. These stimuli causes’ changes in the inner mitochondrial membrane 
resulting in mitochondrial membrane permeabilisation, loss of mitochondrial 
transmembrane potential and release of mitochondrial proteins from the inner 
membrane (Elmore, 2007) such as cytochrome c, Smac/DIABLO (Second 
mitochondrial derived activator of caspases) etc. Cytochrome c causes 
apoptosis by interacting with Apaf-1 and caspase 9 to form the apoptosome 
complex, which leads to programmed cell death. 
 
 
 
 
 
 
 
 
 
 
 
These mitochondrial apoptotic events are regulated by members of the Bcl-2 family 
of proteins that govern mitochondrial membrane permeability. Some of the family 
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members are anti-apoptotic such as Bcl-2 and Bcl-xl that preserve mitochondrial 
integrity (Kluck et al, 1997; Yang et al, 1997), while others are pro-apoptotic like Bax 
and Bak that move from the cytosol into the mitochondria in response to apoptotic 
stimuli and promote mitochondrial protein release by forming pores in the outer 
mitochondrial membrane (Gross et al, 1999). 
Recently, a new mechanistic model has been proposed by the Zwacka/Mohr 
laboratory that is based on their novel findings in HCT116 colon cancer cell lines. 
This model links the extrinsic and intrinsic pathways of apoptosis in response to 
cytotoxic drug 5-Flurouracil (5-FU). The drug triggers death receptor independent 
caspase 8 activation by the FADDosome complex consisting of FADD, RIP-1, 
caspase 8 and caspase 10 (Personal communication). On activation, caspase 8 
then cleaves BH3 protein, BID to its truncated form t-BID, which can then 
translocate to the mitochondria and activate pro-apoptotic members of Bcl-2 family 
of proteins, Bax and Bak leading to mitochondrial membrane permeabilisation and 
release of proapoptotic proteins from mitochondria. Cleavage of BID to t-BID is 
modulated by TRAIL-R2 (DR5) receptor which is activated independent of its ligand 
and stimulates JNK signalling through JIST complex leading to activation of the 
WIP-1 phosphatase. WIP-1 dephosphorylates BID so that caspase 8 mediated 
cleavage of BID can take place as shown in figure 2. 
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Figure 2- The mechanistic 5-FU induced DR5 regulated apoptotic model. The model 
depicts the cytotoxic drug induced caspase 8 activation and JNK signalling by DR5 
receptor leading to apoptosis by promoting BID cleavage and downstream release of 
Smac/DIABLO which functions to inhibit XIAP causing effector caspases mediated 
programmed cell death (Personal communication). 
 
DR5 is a membrane protein that has high homology to members of TNF family and 
induces apoptosis selectively in human tumours but not in normal cells as normal 
cells are protected from TRAIL induced apoptosis by TRAIL-R3 and TRAIL-R4 
which are decoy receptors that lack cytoplasmic death domains (Wu et al, 1997; 
Degli-Esposti et al, 1997) and are unable to induce apoptosis. TRAIL-R3 which is a 
299 amino acid long protein contains only two out of four pseudo repeats which are 
characteristic of extracellular domain of TNF receptor family due to which it diverts 
the death receptor mediated signalling thereby providing TRAIL selectivity. TRAIL-
R4 has been shown to not just prevent apoptosis but also induce cell survival. It can 
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activate NF-kB which induces transcription of anti-apoptotic genes in the cell 
thereby preventing apoptosis (Degli-Esposti et al, 1997). 
Downstream signalling commenced by 5-FU and modulated by DR5 lead to release 
of Smac/DIABLO from mitochondria which plays an more important role in the novel 
apoptotic model by promoting caspase activation and cell death. Smac/DIABLO is 
synthesised as a 239 amino acid long amphipathic protein. It forms a mature 
Smac/DIABLO after cleavage of its mitochondrial targeting signal at the N-terminus 
following its import into the mitochondria (Du et al, 2000). After dimerisation with 
other Smac monomers, an arch shaped Smac/DIABLO dimer is formed with amino 
terminal on the top and carboxyl terminal at the feet of the arch (Chai et al, 2000). 
The function of Smac/DIABLO is similar to Reaper, Hid and Grim which are 
drosophila proteins that mediate apoptosis. The primary sequence of 
Smac/DIABLO is completely different from the drosophila homologs even though 
they have similar function. This may be due to independent evolution of these 
proteins which is termed as convergent evolution (Du et al, 2000). 
Smac/DIABLO functions to activate caspase 9 and effector caspases by 
neutralising the inhibitory effect of family of proteins labelled as Inhibitors of 
Apoptosis Proteins (IAPs) (Du et al, 2000) which are 57 kDa proteins that inhibit 
programmed cell death. 700 IAPs have been discovered including X chromosome 
linked IAP (XIAP), C-IAP1, C-IAP2, NAIP, Survivin, ML-IAP (Huang et al, 2001). 
These IAPs directly supress the caspases or regulate cell-cycle, protein degradation 
and even regulate caspase-independent signal transduction cascade. They have 
two main motifs namely the conserved Baculovirus IAP repeat called as BIR domain 
and RING domain which is found at the C-terminus of the protein (Takahashi et al, 
1998).  
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XIAP inhibits apoptosis by binding to the N-terminus of the linker peptide of active 
caspase 9 which is associated with Apaf-1 and cytochrome c forming an 
apoptosome complex. The binding takes place with the BIR3 domain of XIAP and 
prevents caspase 9 function (Srinivasula et al, 2001). XIAP can also associate with 
effector caspases such as caspase 3 and caspase 7 and supress their activity. But 
the site of interaction is near the BIR2 domain rather than BIR3 domain as seen 
with caspase 9. The XIAP protein binds to the caspases in opposite orientation to 
the original substrate of caspases and thereby completely block the active site 
(Salvesen et al, 2002). 
Smac/DIABLO inhibits the activity of XIAP by binding to the BIR3 domain. The 
residues 56-59 of Smac/DIABLO are analogous to the caspase 9 motif that interacts 
with BIR3 domain of XIAP and thereby prevents caspase 9 binding by competitive 
inhibition. At the same time, Smac/DIABLO also interacts strongly with the BIR2 
domain of XIAP which facilitates Smac-XIAP complex formation that takes place by 
a network of hydrogen bonding and extensive van der Waal networks. Interaction 
of amino acid, alanine in Smac/DIABLO with the hydrophobic pocket in the surface 
groove of XIAP also promotes the complex formation. The Smac-XIAP complex 
prevents the suppression of caspases thereby leading to apoptosis (Srinivasula et 
al, 2001). 
As Smac/DIABLO has been shown to play an important role in 5-FU induced 
apoptosis, various techniques can be used to study Smac/DIABLO release from the 
mitochondria into the cytosol including subcellular fractionation and western blotting 
as well as immunocytochemistry which can determine Smac/DIABLO release at a 
single cell level. In the present project we plan to develop a novel FACS based 
Smac/DIABLO release assay using para-formaldehyde as fixative and detergents 
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to create pores for anti-Smac/DIABLO antibody to traverse through the cell 
membrane and bind to Smac/DIABLO. Using this assay we will compare 
Smac/DIABLO release in 5-FU stimulated HCT116 cells and HCT116shDR5 cells, 
which have silenced DR5 receptor to confirm the importance of DR5 as a modulator 
of apoptosis according to the mechanistic model proposed by the Mohr/Zwacka 
laboratory. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
12 
 
4. Materials and Methods 
 
4.1. Cell culture 
 
The HCT116 colon cancer cell line (ATCC) and its derivate cell line HCT116shDR5 
(provided by Dr. Andrea Mohr) were cultured in McCoy’s medium (Lonza) 
supplemented with 10% Foetal calf serum (Life Technologies) and 1% Penicillin-
Streptomycin (Sigma) at 37˚C in humified air containing 5% CO2.  
4.2. Regents and antibodies 
 
Nicoletti buffer was prepared by adding 1% Sodium Citrate (Sigma) and Triton X100 
(Sigma) to distilled water and mixing Propidium Iodide in the ratio 1:25 on ice. 1X 
Phosphate Buffer Saline (PBS) was prepared by adding 8 g of NaCl, 0.2 g of KCl, 
1.44 g of Na2HPO4, 0.24 g of KH2PO4 in 800 ml of distilled water and adjusting the 
pH to 7.4. The 4% Paraformaldehyde (PFA) was prepared by adding 4 g of PFA 
(Sigma) in 100 ml of PBS (Sigma) and heat stirring until a clear solution was formed. 
0.01% PFA and 0.12% PFA were then prepared from the 4% PFA stock solution by 
dilution in PBS (Sigma). The 0.1% Saponin was made from a 5% stock solution 
containing 0.25 g of Saponin (Sigma) in 5 ml of PBS (Sigma). The working 
concentration of 200 µM of 5-Flurouracil (5-FU, Sigma) was achieved by diluting the 
10 mM 5-FU stock in medium that was then used to treat the cells. 40 nM DIOC(6)3 
(Life Technologies) was made from a 100 mM DIOC(6)3 stock solution by diluting it 
with warm PBS (37˚C, Sigma). Antibodies used in the study were IgG blocking 
antibody (Sigma), mouse anti-Smac/DIABLO antibody (Abcam), FITC labelled 
mouse IgG antibody (Southern Biotechnology) and IgG2b Isotype antibody 
(Biolegend). 
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4.3. Measurement of Apoptosis 
 
Unstimulated and 5-FU (200 µM) stimulated HCT116 and HCT116shDR5 cells were 
cultured in 24 well plates for 24 hours, 36 hours and 48 hours and apoptosis was 
measured according to the protocol by Nicoletti et al (1991). 1000 events per sample 
were measured by FACS Accuri and the sub-G1 cells were counted as apoptotic. 
4.4. Trypan Blue Exclusion method 
 
Unstimulated HCT116 cells fixed with different concentrations of PFA and 
permeabilised with varying concentrations of Saponin were stained with 0.1% 
Trypan blue dye (Sigma) to count the number of intact and permeabilised cells for 
optimisation of the conditions for the Smac/DIABLO release assay. Intact cells have 
an undamaged cell membrane and they do not take up the dye whereas 
permeabilised cells readily take up the Trypan blue dye and are stained blue. 
4.5. Analysis of Smac/DIABLO release 
 
Unstimulated and 5-FU (200 µM, for 24 hours, 36 hours and 48 hours) stimulated 
HCT116 and HCT116shDR5cells, cultured in 25-cm2 flasks (Sarstedt) were 
harvested and washed with PBS (Sigma) followed by 20 minutes of pre-fixation with 
PFA (0.01%, Sigma) on ice. At each step the reagents were mixed by flicking the 
tubes 5 times with no harsh pipetting done. The cells were then fixed with PFA 
(0.12%, Sigma) for 20 minutes and permeabilised with 0.1% Saponin for 5 minutes 
on ice. For detergent mediated permeabilisation step, the cells stimulated with 5-FU 
were flicked until the pellet was dislodged from the wall of the tube and then the 
same number of flicks were applied on the other samples. Unspecific binding of anti-
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Smac/DIABLO antibody was blocked with 5 µg of mouse IgG antibody (Sigma). 1 
mg/ml anti-Smac/DIABLO antibody (Abcam) was added for additional 20 minutes 
at 4˚C and IgG2b Isotype antibody (Biolegend) was used as control. The cells were 
incubated with FITC labelled mouse IgG secondary antibody (Southern 
Biotechnology) for 20 minutes on ice and in the dark. Samples were then analysed 
by FACS Accuri and 10,000 events per sample were acquired and analysed.  
4.6. Measurement of mitochondrial membrane polarity and apoptosis 
inhibition by Zvad 
 
Unstimulated and 5-FU (200 µM, for 24 hours and 48 hours) stimulated HCT116 
cells, cultured in 25-cm2 flasks (Sarstedt) were harvested and washed with warm 
PBS (Sigma). 40 nM DIOC(6)3 (Life Technologies) was added and the cells were 
incubated in a water bath at 37˚C for 15 minutes. 10,000 events per sample were 
measured immediately by FACS Accuri. HCT116 cells were also treated with Zvad, 
a pan caspase inhibitor with and without 5-FU (200 µM, Sigma) for 48 hours to 
examine Smac/DIABLO release and apoptosis was also measured according to the 
protocol by Nicoletti et al (1991) by FACS Accuri. 
4.7. Statistical Analysis 
 
Experiments were performed in triplicates and the experimental values were 
expressed as mean value +/- standard deviation (S.D.). For significant analyses, 
ANOVA was used with p˂ 0.05 considered as significant and p˂ 0.001 as highly 
significant. 
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5. Results 
 
5.1. Measurement of apoptosis 
 
According to the novel 5-FU induced and DR5 modulated apoptotic model proposed 
by the Mohr/Zwacka laboratory when 5-FU induces apoptosis, Smac/DIABLO 
release takes place from mitochondria. We determined the level of apoptosis 
induced by 5-FU using a DNA hypodiploidy assay, also known as Nicoletti assay, 
described by Nicoletti et al (1991) in 5-Flurouracil (5-FU) stimulated HCT116 cells 
and observed an increase in apoptosis with increasing time points of 5-FU 
stimulation. We measured apoptosis levels of 35% at 48 hours of treatment with just 
above 5% apoptosis at 24 hours and 15% at 36 hours of treatment with 5-FU 
respectively (Figure 3).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3-Measurement of apoptosis in HCT116 cells with DNA hypodiploidy 
assay using Propidium Iodide. Difference in percentage of apoptosis in HCT116 
cells induced with 5-FU (200 µM) for 24 hours, 36 hours and 48 hours was analysed 
as compared to untreated control using method described by Nicoletti et al (1991). 
Error bars denote the standard deviation of mean of triplicate samples. 
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The exact molecular mechanism of 5-FU induced apoptosis mediated by the 
Mohr/Zwacka apoptotic model involving death receptor independent caspase 8 
inducing complex is still not clear. But the important role of DR5 in regulating this 
mechanistic apoptotic model has been illustrated by the apoptosis assay performed 
on DR5 knockdown cells (HCT116shDR5 cells). The percentage of apoptosis was 
compared with HCT116 wild type cells by treatment with 5-FU for 24 hours, 36 hours 
and 48 hours and significant differences in apoptosis were observed between these 
cell lines (Figure 4). A highly significant difference was seen especially at 48 hours 
of stimulation with 35% apoptosis in HCT116 wild type cells in comparison to 18% 
in DR5 knockdown cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4- Comparison of apoptosis in HCT116 and HCT116shDR5 cells after 
stimulation with 5-FU at different time points. HCT116 and HCT116shDR5 cells 
were treated with 200 µM 5-FU for 24 hours, 36 hours and 48 hours and percentage 
of apoptosis was measured by Nicoletti assay as compared to untreated controls. Blue 
bars represent HCT116 cells and orange bars represent HCT116shDR5 cells with 
error bars denoting the standard deviation of mean of triplicate samples. The difference 
in percentage of apoptosis between HCT116 and HCT116shDR5 cells is significant. 
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Du et al (2000) has already shown the important role played by the mitochondrial 
protein Smac/DIABLO in apoptosis by preventing the inhibitory action of XIAP on 
caspases thereby leading to caspase activation and programmed cell death. But it 
is necessary to fully understand the relationship between the release of 
Smac/DIABLO and apoptosis induced by drug 5-FU in the context of the novel 
apoptotic model. Therefore, we sought to develop and establish an easy and quick 
Smac/DIABLO release assay. 
5.2. Establishment of a FACS based Smac/DIABLO release assay 
 
5.2.1. Examination of different concentrations of Saponin at different time points 
for membrane permeabilisation 
 
To analyse the Smac/DIABLO release induced by 5-FU, a FACS based 
Smac/DIABLO release assay was developed. The method involved a 
Smac/DIABLO specific antibody to traverse the plasma membrane of the cells, after 
a detergent created pores large enough for the Smac/DIABLO antibody to pass 
through. Saponin was used as the detergent to permeabilise the cell membrane and 
different concentrations of Saponin such as 0.1%, 0.2%, 0.5%, 1% and 5% were 
used together with 4% Paraformaldehyde (PFA) for fixation for different time points 
ranging from 3 minutes to 30 minutes. Permeabilised cells were counted using the 
Trypan Blue Exclusion method. In response to these experiments 0.5%, 1% and 
5% Saponin concentrations were discarded as cell breakdown was observed at all 
the time points. Better results were observed for 0.1% and 0.2% of Saponin without 
signs of breakdown and loss of cells. Furthermore, the cells had to endure four 
rounds of washing with PBS according to protocols for intracellular staining. We 
found that it was only with 0.1% Saponin and a 5 minute incubation period that cells 
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Figure 5- Schematic diagram to illustrate the steps for examining different 
concentrations of Saponin for permeabilisation. 0.1% Saponin was selected from 
different concentrations of Saponin such as 0.2%, 0.5%, 1% and 5% for 
permeabilisation with incubation period of 5 minutes using two main criterion namely 
presence of permeabilised cells at lowest incubation period and observation of a 
pellet of cells after four washing steps. These criterions were used to determine the 
correct concentration of Saponin to use for permeabilisation in FACS based 
determination of Smac/DIABLO release assay.  
were observed after repeated washing, so it was chosen for later experiments 
(Figure 5). 
 
 
 
 
 
 
 
 
 
 
 
5.2.2. Assessment of different concentrations of PFA for cell fixation 
 
The combination of 0.1% Saponin for 5 minutes and 4% PFA was tested on HCT116 
cells stimulated with 5-FU for 48 hours for fixation and permeabilisation. But 
stimulated cells were sensitive and a significant proportion of cells were lost after 
the fourth and final washing step and consequently no signal could be detected in 
the flow cytometer. A lower concentration of Saponin i.e. 0.05% was also tested but 
the same result was observed. So it was concluded that over fixation as opposed to 
higher detergent concentration was leading to the loss of cells and signal. Thus, the 
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Table 1- Analysis of different concentrations of PFA for fixation of HCT116 cells 
on the basis of two main criterion. 
 
 
 
 
 
 
 
 
 
 
concentration of PFA was decreased to 2%, 1% and 0.5%. The total number of 
permeabilised cells observed after Trypan Blue staining in the haemocytometer at  
these concentrations of PFA were the same. But a cell pellet was present only with 
0.5% PFA after four rounds of washing as outlined in Table 1. 
 
 
 
 
 
 
 
 
When Smac/DIABLO release was measured after fixation with 0.5% PFA using 
FACS, a shift in signal was observed with 5-FU treated samples as compared to 
control (Figure 6) suggesting that the antibody detected Smac/DIABLO in the 
cytosol which is released from the mitochondria to induce apoptosis in response to 
5-FU. This release was seen as a shift in the signal towards higher fluorescence 
intensity. With a modest signal detected in the pilot experiment, the concentration 
of PFA was further decreased to improve the method and 0.12% PFA was chosen 
as at this concentration we could increase the number of cells that survived the 
washing steps and use for the FACS analysis. When a pre-fixation with 0.01% PFA 
was added before the fixation step and 0.1% Saponin for 5 minutes was used for 
permeabilisation, a larger pellet was observed. 
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Figure 6- Analysis of Smac/DIABLO release in HCT116 cells. Untreated HCT116 
cells incubated with Smac/DIABLO antibody (A), stained with Isotype control antibody 
(B) and treated with 5-FU (200 µM) for 48 hours (C) were analysed for Smac/DIABLO 
release using 0.5% PFA as a fixative and 0.1% Saponin for 5 minutes for 
permeabilisation of cells. The shift in the fluorescence signal between A and C is 
represented by blue dotted line and blue double arrow whereas the shift in the 
fluorescence signal between B and C is depicted by green dotted line and green double 
arrow. The shift in fluorescent signal in C as compared to A and B indicates 
Smac/DIABLO release. P2 represents the percentage of morphologically unchanged 
cells as gated in the Forward/Side-scatter plot of the FACS analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
With a large number of cells and a significant shift in the signal, the protocol for 
FACS based Smac/DIABLO release was established to involve pre-fixation of the 
cells with 0.01% PFA, fixation with 0.12% PFA and permeabilisation with 0.1% 
Saponin for 5 minutes leading to creation of pores in the plasma membrane for 
Smac/DIABLO antibody to enter the cells and bind to its target protein. The 
Smac/DIABLO release was then measured by FACS and the efflux of 
Smac/DIABLO from the mitochondria was detected only in 5-FU stimulated cells as 
P2 
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Figure 7- Schematics of Saponin permeabilised HCT116 cells to detect 
Smac/DIABLO release in the cytosol by flow cytometry. Untreated and 5-FU treated 
cells were pre-fixed with 0.01% PFA, fixed with 0.12% PFA and permeabilised with 0.1% 
Saponin to create pores in the cells for antibody specific for Smac/DIABLO to travel 
through the plasma membrane. Primary antibody and FITC labelled secondary antibody 
was added and Smac/DIABLO release was measured by FACS. In untreated cells, there 
was no apoptosis due to which no Smac/DIABLO was released in the cytosol for 
antibody binding. In 5-FU stimulated cells, Smac/DIABLO was released from the 
mitochondria due to induction of apoptosis so that antibody could bind Smac/DIABLO in 
the cytosol and the signal was detected using FACS. 
compared to untreated control (Figure 7). The presence of Smac/DIABLO in the 
cytosol was observed as a shift in the fluorescent signal in 5-FU treated cells as 
compared to untreated control (Figure 8). Using this assay, Smac/DIABLO release 
was also measured in DR5 knockdown cells to understand the role played by DR5 
receptor according to the novel apoptotic model as proposed by the Mohr/Zwacka 
laboratory. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
FACS Analysis  
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Figure 8- Examination of cytosolic Smac/DIABLO release in 5-FU stimulated 
HCT116 cells using FACS. HCT116 cells were stimulated with 200 µM 5-FU for 48 
hours as compared to untreated cells and Smac/DIABLO release was analysed after 
morphologically unchanged cells were identified in Forward/Side-scatter plot. A shift in 
peak was observed for cells induced with 5-FU as compared to untreated control 
depicting Smac/DIABLO release from mitochondria. 
 
5.3. Examining Smac/DIABLO release according to the novel apoptotic 
model 
 
Specificity of the assay was determined by comparing the Smac/DIABLO release in 
cells treated with 5-FU to untreated cells and cells stained with Isotype antibody. It 
was observed that untreated control and Isotype control had a similar fluorescent 
signal (Figure 9). Whereas, in 5-FU stimulated cells there was a shift in the signal 
as compared to the controls. Keeping the fluorescent signal of untreated control and 
Isotype control as threshold, the shift in the peak observed in 5-FU treated cells 
signified Smac/DIABLO release. The major advantage of this FACS based assay is 
that it allowed us to measure Smac/DIABLO release at the single cell level and 
when Smac/DIABLO release was analysed after gating the morphologically 
unchanged cells by Forward/Side-scatter plot, it was observed that 89.7% of 
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Figure 9- Comparison between the controls used in Smac/DIABLO release 
assay. HCT116 cells were incubated with Smac/DIABLO antibody and cells were also 
stained with Isotype control antibody forming the untreated control and untreated 
Isotype control respectively. Smac/DIABLO release was analysed in these samples 
as described in Materials and Method and overlapping fluorescence signals were 
observed. 
HCT116 cells stimulated with 5-FU for 48 hours released Smac/DIABLO as 
compared to untreated controls (Figure 10). 
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Figure 10- Analysis of Smac/DIABLO release at a single cell level after treatment 
of cells with 5- FU (200 µM). Smac/DIABLO release was examined in untreated 
HCT116 cells incubated with Smac/DIABLO antibody (A), stained with Isotype control 
antibody (B), cells treated with 5-FU for 48 hours and incubated with Smac/DIABLO 
antibody (D). M1 represents the percentage of cytosolic Smac/DIABLO release from 
the cells. Maximum Smac/DIABLO release was observed in 5-FU stimulated cells 
incubated with Smac/DIABLO antibody with M1 equal to 89.7%. 
 
 
 
 
 
 
 
 
 
 
 
 
We have determined Smac/DIABLO release from the mitochondria at 48 hours of 
treatment with 5-FU. In order to examine if the 48 hours of 5-FU stimulation is the 
lowest time point of apoptosis induction, Smac/DIABLO release was compared in 
treated cells at different time points namely 24 hours, 36 hours and 48 hours. It was 
observed that the signal in 24 hours of treatment was similar to untreated control 
and Isotype control (Figure 11) demonstrating that no Smac/DIABLO release has 
taken place at this time point as there was no shift in the signal. Similarly, the 
fluorescent signal at 36 hours of 5-FU induction overlapped with the untreated 
control (Figure 12) thus confirming that Smac/DIABLO release which is 
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Figure 11- Examination of Smac/DIABLO release in HCT116 cells at different 
time points of 5-FU treatment. HCT116 cells were treated with 5-FU for 24 hours 
and 48 hours and Smac/DIABLO release was measured according to Smac/DIABLO 
release assay described in Materials and Methods. Smac/DIABLO release signal 
after 24 hours of 5-FU stimulation was observed to be similar to untreated control 
and untreated Isotype control in which untreated cells were incubated with 
Smac/DIABLO antibody or stained with Isotype antibody respectively. The shift in 
signal was only seen after 48 hours which is characteristic of Smac/DIABLO release. 
characterised by shift in the signal takes place only at 48 hours of 5-FU induction. 
These results are in accordance with the results obtained by the Nicoletti assay as 
shown in Figure 3 in which maximum apoptosis was observed at 48 hours of 5-FU 
treatment as compared to 24 hours and 36 hours indicating that Smac/DIABLO 
release leads to increased apoptosis in the cells. 
These results were quantified by determining the Mean Fluorescence Intensity 
Ratio (MFI Ratio) of the above samples in which maximum fluorescence intensity 
was observed at 48 hours of 5-FU induction as compared to 24 hours and 36 hours 
of treatment (Figure 13).  
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Figure 12- Examination of cytosolic Smac/DIABLO release after stimulation with 
5-FU for 36 hours as compared to 48 hours of stimulation. HCT116 cells were 
treated with 5-FU for 36 hours and 48 hours and Smac/DIABLO release was analysed 
as compared to untreated cells. The fluorescent signal of cells treated with 5-FU for 
36 hours was similar to untreated control and untreated Isotype control in which 
untreated cells were incubated with Smac/DIABLO antibody or stained with Isotype 
antibody respectively. The shift in signal, which is characteristic of Smac/DIABLO 
release was observed at 48 hours of 5-FU stimulation only. 
 
 
 
 
 
 
 
 
 
 
 
Figure 13- Quantification of FACS based Smac/DIABLO release. MFI ratio was 
calculated for HCT116 cells treated with 5-FU for 24 hours, 36 hours and 48 hours in 
comparison to untreated control and highest intensity of fluorescent signal was 
observed at 48 hours of stimulation. Error bars denote the standard deviation of mean 
of triplicate samples. 
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Figure 14- Examination of Smac/DIABLO release in HCT116 and HCT116shDR5 
cells. HCT116 cells and HCT116shDR5 cells were stimulated with 200 µM of 5-FU 
for 48 hours and Smac/DIABLO release was analysed by Smac/DIABLO release 
assay as described in Materials and Methods. Shift in the peak was observed only in 
HCT116 cells depicting Smac/DIABLO release and not in HCT116shDR5 cells. 
Smac/DIABLO release was also accessed in HCT116shDR5 cells (DR5 silenced 
cells) as compared to HCT116 wild type cells and it was seen that Smac/DIABLO 
release in the cytosol takes place only in HCT116 cells which is characterised by a 
shift in the peak as compared to DR5 knockdown cells (Figure 14). This indicates 
that by silencing DR5, the Smac/DIABLO release is inhibited. These results are in 
consensus with level of apoptosis measured in HCT116shDR5 cells (Figure 4) in 
which level of apoptosis dropped from 35% to 15% after knocking down DR5 
receptor in cells treated with 5-FU for 48 hours. Thus manifesting the importance of 
DR5 in modulating Smac/DIABLO release and apoptosis according to the 
Mohr/Zwacka apoptotic model as it was observed that by silencing DR5, the 
Smac/DIABLO release did not take place and consequently complete apoptosis did 
not take occur.  
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Figure 15- Quantification of FACS based release of Smac/DIABLO release by 
MFI ratio. Smac/DIABLO release in HCT116 and HCT116shDR5 cells was quantified 
by determining the Mean Fluorescence Intensity Ratio of cells stimulated with 5-FU 
for 24 hours, 36 hours and 48 hours in comparison to untreated control. Error bars 
denote the standard deviation of mean of triplicate samples. The difference in MFI 
ratio between HCT116 and HCT116shDR5 cells when treated with 5-FU for 48 hours 
is highly significant with p value equal to 0.004. 
 
These results were quantified by measurement of MFI ratio with maximum signal 
intensity observed in HCT116 cells as compared to HCT116shDR5 cells. 
Comparison of fluorescence intensity was also done in these cells at different time 
points of 5-FU stimulation. The results show that MFI ratio was decreased in DR5 
silenced cells at all the time points of 5-FU treatment namely 24 hours, 36 hours 
and 48 hours as compared to wild type HCT116 cells. The reduction in signal 
intensity in DR5 knockdown cells at 48 hours of 5-FU induction was quite significant 
as compared to HCT116 cells (Figure 15). 
 
 
 
 
 
 
 
 
 
 
Using FACS based Smac/DIABLO release assay we have confirmed the 
involvement of 5-FU and DR5 in cytosolic release of Smac/DIABLO which is in 
accordance to the novel apoptotic model that is based on work by the Mohr/Zwacka 
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laboratory. Along with 5-FU and DR5, the model proposes that mitochondrion relies 
on caspases for Smac/DIABLO release. This was validated by performing the FACS 
assay after treating the cells with Zvad, a pan caspase inhibitor and analysing 
Smac/DIABLO release after inhibition of all the caspases. Zvad prevents caspase 
activation by blocking pro-caspases which are inactive forms of caspases from 
activating into active caspases by binding to well conserved allosteric sites in 
caspases to mediate its inhibition (Scheer et al, 2006). Smac/DIABLO release into 
cytosol is usually observed by shift in the fluorescent signal as compared to 
untreated controls but the signal in cells treated with Zvad was similar to the 
untreated control indicating that no Smac/DIABLO release from the mitochondria 
took place. Cells treated with both Zvad and 5-FU were also analysed for 
Smac/DIABLO release and no shift in signal was observed indicating that even in 
the presence of 5-FU which is a cytotoxic drug that induces apoptosis, Zvad could 
inhibit Smac/DIABLO release (Figure 16). Thus, confirming an important role of 
caspases in Smac/DIABLO release from the mitochondria. 
Level of apoptosis was also measured by Nicoletti assay in presence of Zvad which 
was observed to be only 3% as compared to 43% in cells stimulated with 5-FU 
(Figure 17) indicating that by suppression of caspases and therefore Smac/DIABLO 
release into cytosol, apoptosis was also blocked. 
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Figure 16- Examination of Smac/DIABLO release in presence of Zvad, a pan-
caspase inhibitor. Smac/DIABLO release was analysed in HCT116 cells treated with 
Zvad and 5-FU in comparison to untreated cells treated with Zvad alone. 
Smac/DIABLO release in these samples were then analysed with cells stimulated with 
5-FU for 48 hours and untreated control. The analyses were done after morphologically 
unchanged cells were gated in Forward/Side-scatter plot. Shift in the peak was 
observed only in cells stimulated with 5-FU for 48 hours. The fluorescent signals of 
cells stimulated with Zvad and 5-FU and with Zvad only were similar to untreated 
control depicting no Smac/DIABLO release. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17- Measurement of apoptosis in HCT116 cells in presence of Zvad, a pan 
caspase inhibitor. Level of apoptosis was examined by Nicoletti assay in HCT116 cells 
when they were induced with 200 µM 5-FU for 48 hours in comparison to cells treated 
with Zvad and 5-FU. These samples were also compared with unstimulated cells treated 
with Zvad only and untreated control. Error bars denote the standard deviation of mean 
of triplicates samples.  
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5.4. Connecting the dots 
 
With the finding that Smac/DIABLO release and apoptosis takes place only after 48 
hours of 5-FU stimulation as compared to 24 hours and 36 hours of 5-FU treatment, 
the final piece of the puzzle was to determine the reason behind this observation. 
Membrane polarity was determined by 3-3ʹ dihexyloxacarbcyanine iodide 
(DIOC(6)3) which is a hydrophilic fluorescent dye that stains mitochondrial 
membrane. Using DIOC(6)3 stain, it was observed that membrane depolarisation 
which is one of the characterising feature of programmed cell death and occurs 
early in apoptosis takes place only after 48 hours of 5-FU stimulation in comparison 
to 24 hours of treatment with 5-FU (Figure 18).  Depolarisation of the membrane 
was observed as a shift in the fluorescent signal as compared to untreated control. 
At 24 hours of treatment, there was only a slight shift in the signal indicating that 
some amount of membrane depolarisation has taken place but at 48 hours of 5-FU 
induction there was a greater shift in the signal as compared to untreated control 
and 24 hours of 5-FU treatment. This result was in accordance with Figure 3 and 
Figure 11 representing that maximum amount of Smac/DIABLO release and highest 
percentage of apoptosis takes place at 48 hours of 5-FU stimulation may be 
because complete depolarisation of the mitochondrial membrane to facilitate 
Smac/DIABLO release into cytosol and later apoptosis only takes place at this time 
point. 
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Figure 18- Measurement of mitochondrial membrane depolarisation by DIOC(6)3 
staining. Membrane depolarisation was measured by staining with DIOC(6)3 in cells 
stimulated with 5-FU for 24 hours (A) and for 48 hours (B). Membrane polarity was 
compared in the treated cells as compared to untreated control (C). Membrane 
depolarisation in 5-FU induced cells was more than the untreated control as seen by 
a shift in the fluorescence signal but complete depolarisation which was observed by 
a larger shift in the fluorescent signal was observed only at 48 hours of 5-FU induction 
as compared to untreated control. 
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6. Discussion 
 
Our research demonstrates several important findings that increase our 
understanding of the sequence of events and relationships between death receptor 
and intracellular stress mediating cytotoxic drug activated apoptosis. The apoptosis 
mediated by the intracellular stress and death receptor leads to release of inner 
mitochondrial membrane proteins such as cytochrome c and Smac/DIABLO. We 
have developed a FACS based Smac/DIABLO release assay in HCT116 cells 
undergoing apoptosis induced by the drug 5-Flurouracil (5-FU) to better understand 
the link between the release of proapoptotic factors from mitochondria into the 
cytosol and the different programmed cell death pathways. The FACS based 
method is quick, inexpensive and easy to perform as compared to the laborious 
biochemical method involving subcellular fractionation and western blotting using 
specific antibodies on mitochondrial and cytosolic fractions. Our FACS method can 
measure Smac/DIABLO release at single cell level as compared to western blotting 
which analyses the intracellular protein release in a whole cell population making it 
difficult to determine if Smac/DIABLO release has taken place in all the cells or if it 
is a partial redistribution in a small percentage of cells (Waterhouse and Trapani, 
2003). Potentially, the FACS method can selectively analyse cancer cells in primary 
tumour material using specific surface markers along with anti-Smac/DIABLO 
antibody whereas in order to achieve the same by western blotting the cells need 
to be sorted first for identification followed by characterisation of tumour cells, which 
is time consuming and expensive. 
The FACS based assay involves the use of Paraformaldehyde (PFA) for pre-fixation 
which preserves the integrity of the cells preventing their loss in subsequent steps 
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and use of Saponin for permeabilisation which creates pores in the membrane for 
antibody to traverse through and bind to Smac/DIABLO. The assay detects release 
of Smac/DIABLO on induction of apoptosis by formation of channels through the 
action of Bcl-2 family of proteins which can be pro-apoptotic such as the BH3 only 
protein, BID and multi domain proteins Bax and Bak or anti-apoptotic such as Bcl-2 
and Bcl-xl (Kuwana et al, 2002). These proteins when oligomerise on the outer 
mitochondrial membrane form pores as they have structures similar to pore forming 
domain of diphtheria toxin and bacterial colicin leading to escape of large 
macromolecules such as Smac/DIABLO (Martinou and Green, 2001). It has been 
suggested by Adrian et al (2001) that when cytochrome c appears in the cytosol it 
forms the apoptosome complex leading to caspase activation which causes swelling 
of the mitochondrial matrix and formation of mega pores in the inner and outer 
mitochondrial membranes leading to Smac/DIABLO release (Martinou and Green, 
2001). This caspase mediated feedback loop is important as caspase activity can 
be inhibited by XIAP which is counter measured by Smac/DIABLO release that 
binds to XIAP and neutralises its activity thereby leading to apoptosis (Adrian et al, 
2001) as shown in Figure 19.  
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Figure 19- Model illustrating the dependence of Smac/DIABLO release on 
executioner caspases. According to this model, Bcl-2 regulates cytochrome c release 
from the mitochondria and on its release, cytochrome c interacts with protein Apaf-1 and 
caspase 9 forming apoptosome complex which activates executioner caspases leading 
to programmed cell death. Activity of the caspases can be blocked by inhibitory protein 
XIAP. As a counter measure these caspases mediate Smac/DIABLO release from the 
mitochondria by attacking the outer membrane and leading to formation of mitochondrial 
pores for Smac/DIABLO release. Smac/DIABLO in turn inhibits the activity of XIAP 
thereby promoting caspase mediated apoptosis (Adrian et al, 2001).  
 
In contrast to the mechanism proposed by Adrian et al (2001), we tested a novel 
model according to which caspases can act upstream of mitochondria in stress 
induced apoptosis and not just downstream. This mechanistic model is proposed 
by the Mohr/Zwacka laboratory describing the role of caspase 8 in cleaving the BH3 
only protein, BID to its truncated form t-BID which in turn promotes mitochondrial 
protein release. This was confirmed by measuring Smac/DIABLO release in cells 
treated with Zvad, a pan caspase inhibitor and it was observed that Smac/DIABLO 
release was impeded (Figure 16 and Figure 17) due to inhibition of caspases acting 
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upstream of mitochondria. The most prominent candidate in such a role is caspase 
8. 
Caspase 8 which has been proposed to act upstream of mitochondria is a part of a 
complex called as FADDosome consisting of FADD, RIP-1 , caspase 8 and caspase 
10 in 5-FU induced apoptosis (Personal communication). In this complex pro-
caspase 8 is activated by homotypic interactions (Hoffman et al, 2009) with other 
members of the FADDosome complex subsequently leading to cleavage of BID to 
t-BID which then activate Bax and Bak that inserts into the outer mitochondrial 
membrane to form channels (Kuwana et al, 2002). 
This model also links the intrinsic pathway of apoptosis which is initiated by cytotoxic 
drug 5-FU to the extrinsic apoptotic pathway involving a death receptor to mediate 
programmed cell death. Usually caspase 8 activation is induced by death receptors 
via FADD mediated recruitment of caspase 8 to the DISC complex. But 5-FU can 
activate caspase 8 independent of a death receptor through the FADDosome 
complex. According to the model, TRAIL-R2 (DR5) a death receptor, modulates 
apoptosis not by caspase-8 activation but by JNK signalling. DR5 belongs to the 
family of Tumour Necrosis factor (TNF) superfamily of receptors which also includes 
TNFR-1, Fas (CD95), TRAIL-R1 (DR4), DR3 and DR6 that contains a death domain 
to modulate the apoptotic program (Shirley et al, 2011). 5-FU up regulates DR5 that 
in turn activates c-Jun-N-terminal protein kinase (JNK) that belongs to Mitogen 
activated protein kinase (MAPK) superfamily. JNK itself is activated by sequential 
phosphorylation by MAP4Ks and MAP3Ks such as Ask-1 followed by tyrosine and 
threonine phosphorylation catalysed by members of MAP2K family (Cowan et al, 
2003; Dhanasekaran and Reddy, 2008) such as MKK4 and MKK7 which activate 
JNK and lead to activation of the Activator Protein 1 (AP-1) transcription factor. AP-
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Figure 20 - Comparison in apoptosis between HCT116 cells and HCT116shDR5 
cells. According to work by Mohr/Zwacka and the resulting model of apoptosis, silencing 
of DR5 receptor blocks Smac/DIABLO release by inhibition of JNK signalling pathway. 
JNK activates WIP-1 phosphatase that dephosphorylates BID so that caspase 8 
mediated cleavage to t-BID can take place. But due to DR5 knockdown, t-BID formation 
is blocked thereby preventing Smac/DIABLO mediated inhibition of XIAP protein causing 
obstruction of caspase activation and inhibition of apoptosis.   
1 is a protein complex and consists of c-Jun, members of Fos family and activating 
transcription factor family, respectively (Liu et al, 2000). Activated AP-1 leads to 
transcriptional up-regulation of the WIP-1 phosphatase (Song et al, 2010), which 
regulates BID dephosphorylation and subsequent cleavage. We have observed that 
following DR5 knockdown by RNA interference, Smac/DIABLO release and 
apoptosis is blocked as shown in Figure 14 and Figure 4 respectively due to 
inhibition of signalling normally emanating from DR5 and mediated through JNK. 
These observations suggest that DR5 may be a critical factor in Smac/DIABLO 
release and lack of DR5 might serve as a predictive marker for 5-FU responses 
(Figure 20). 
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The monoclonal antibody that detects Smac/DIABLO release recognises it in the 
cytosol which is observed as a shift in the Smac/DIABLO signal in apoptotic cells 
as compared to controls (Figure 8). Whereas, when cytochrome c is detected by 
FACS in mitochondria a reduction in signal is observed (Stahnke et al, 2004) rather 
than a upward shift in the signal indicating that antibody detects cytochrome c in 
mitochondria and on induction of apoptosis when cytochrome c is released from the 
mitochondria into the cytosol the signal then decreases, which is most likely due to 
a corresponding conformational change in cytochrome c and failure of the antibody 
to recognise cytochrome in this altered state. This led us to ask what limits and 
facilitates the interaction of antibody to Smac/DIABLO in the cytosol. Three theories 
are available to explain it. Firstly, it is possible that our Smac/DIABLO antibody 
cannot enter the mitochondria unlike 7H8.2C12, the cytochrome c antibody which 
detects cytochrome c inside the mitochondria (Stahnke et al, 2004) and that the 
Smac/DIABLO antibody can only detect the protein when it is released into the 
cytosol during apoptosis.    
Secondly, according to Srinivasula et al (2001) when Smac/DIABLO is released 
from the mitochondria into the cytosol it performs a major function of binding to XIAP 
protein. XIAP belongs to a family of Inhibitors of Apoptosis Proteins (IAP) that 
regulates apoptosis downstream of mitochondria. XIAP specifically interacts with 
effector caspases, inhibits them and thereby prevents apoptosis. Smac/DIABLO 
binds to the third Baculovirus IAP repeat (BIR) domain of XIAP so that XIAP 
mediated caspase inhibition is released leading to apoptosis. Smac/DIABLO 
undergoes hydrogen bonding and van der Waal interactions with the BIR3 domain 
forming a Smac-XIAP complex with the N-terminus of Smac/DIABLO binding to the 
39 
 
surface groove of the BIR3 domain thereby preventing the inhibiting contact of XIAP 
with caspases. The formation of the Smac-XIAP complex could affect the binding of 
the Smac/DIABLO antibody to the Smac/DIABLO protein as the binding energy 
between antibodies and their protein antigens are affected by changes in hydrogen 
bonding, van der Waal contacts and hydrophobic interactions in the protein antigen 
(Goshorn et al, 1991). Results that points in this direction were observed  by 
Jemmerson et al (1990) who showed that on its release in T-hybridoma cells, 
cytochrome c undergoes conformational changes may be due to its interaction with 
Apaf-1 and caspase 9 leading to formation of the apoptosome complex. The 
resulting conformational changes causes destabilisation of the tertiary structure of 
cytochrome c leading to opening up of a haeme crevice which is readily detected  
by a monoclonal antibody that binds to the omega loop region around residue 44 
located near the opened haeme crevice. The binding site of our Smac/DIABLO 
antibody has not been identified but based on our findings we expect that 
conformational changes that takes place by formation of Smac-XIAP complex would 
influence the antibody binding in a positive way. 
Thirdly, Smac/DIABLO undergoes maturation in mitochondria by cleavage of its 
signal peptide to gain its apoptotic activity (Du et al, 2000). It is possible that this 
maturation may affect antibody binding to Smac/DIABLO by exposing an epitope 
for antibody interaction. When mature Smac/DIABLO is released into the cytosol 
during apoptosis it can facilitate antibody interaction at the exposed antibody 
binding region which could be detected by FACS as a shift in the fluorescent signal. 
One of the characteristic feature of apoptosis is dissipation of mitochondrial 
membrane potential which regulates the opening up of channels in inner 
mitochondrial membrane for pro-apoptotic protein release and their detection by 
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specific antibody. But in normal cells, membrane polarity is established by transfer 
of electrons through the electron transport chain (ETC) in the inner mitochondrial 
membrane and the movement of protons across the inner membrane from the 
matrix to the inter membrane space. The electron transport takes place by 
mitochondrial respiratory complexes I, II, III and IV as well as lipid soluble electron 
carrier, ubiquinone which is present between complexes I/II and III and water 
soluble electron carrier, cytochrome c which is present between complexes III and 
IV. The transfer of electrons and movement of protons generates ATP by ATP 
synthase which is also called as Complex V and the coupling between electron 
transport and ATP synthesis is called as oxidative phosphorylation. Cytochrome c 
plays an important role in Electron Transport Chain. It receives electrons from 
complex II and complex III and transfer them to oxygen in complex IV (Sun et al, 
2013). During normal conditions when cytochrome c is involved in ATP generation, 
it is sequestered inside the mitochondria and mitochondrial membrane is also in 
resting stage. But on induction of apoptosis, membrane gets depolarised and 
cytochrome c is also released. Besides cytochrome c, our experiments have 
indicated a direct relationship between Smac/DIABLO release and membrane 
depolarisation also. As we have observed that both membrane depolarisation and 
Smac/DIABLO release takes place at the same time point which is at 48 hours of 5-
FU stimulation (Figure 18). Thus indicating that Smac/DIABLO release in cytosol 
also depends on the membrane polarity to mediate apoptosis. 
Thus, the flow cytometric procedure described in this report is useful to understand 
apoptosis by mitochondrial protein release in cancer cells and can help to elucidate 
how apoptosis is regulated at the mitochondrial level in anti-cancer therapy. 
Furthermore, the assay can be used in primary cancer cells to determine their 
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response to chemotherapeutic drugs at a molecular level. Due to cellular, genetic 
and biochemical heterogeneity of the tumour, we can determine if the cancer cells 
are resistant to apoptosis induced by the chemotherapeutic drug using the 
Smac/DIABLO release assay. This information can then be used to modify the drug 
for better therapeutic options and anti-cancer treatment. 
